The patent, which is the company’s first specifically targeting neurological conditions, is granted for the US market and is valid until 2022. The company said that the claims
The multicenter, double-blind, randomized, controlled Phase IIIb trial compares a single dose of Dalvance with the once-weekly dosage regimen of Dalvance in adult patients with ABSSSI. In the
Recently, a double-blind, placebo-controlled, multicenter Phase II trial of three doses of GED-0301 in 166 patients with active Crohn’s disease has been completed. Based on the data, which
Under the deal, Agendia’s oncology biomarker technology will be used in the evaluation of new pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials. Agendia president and
The drug is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis as well as for the management of acute pain
The deal, which is designed to leverage the expertise and experience from both the companies to optimize Biogen Idec’s clinical development processes, is structured to increase clinical trial
As part of the agreement, both the companies will work together to discover and advance candidate inhibitors. Hydra Biosciences president and CEO Russell Herndon said the company is
The company said that graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. Currently, the drug is approved in
A total of 100 patients will be enrolled in the new trial, which will include a randomized control arm and will expand on the results that were showed
The deal will see Medivation secure exclusive worldwide rights for the development and commercialization of these compounds. As part of the deal, Medivation will have access to OncoFusion’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.